Evaluation of the management of severe malaria

We conducted a prospective and descriptive multicenter study from July 2022 to May 2023, a period of 11 months.The aim of this study was to evaluate the management of severe malaria in the community health centers of Filamana, Fakola, Bamba and Guélenikoro in the Sikasso region. The study involved 158 patients presenting with one or more forms of severe malaria according to WHO severity criteria. The predominance of children aged 1 to 5 years was noted (72.3%). The anemic phenotype was the most frequent at 45.4%, while the mixed form was 32.8% and the anemic phenotype 21.5%. IM injectable artemether was used most frequently (59.5%), followed by injectable artesunate (32.9%), and two patients received quinine infusion (1.3%). Relief was mainly provided by artemisinin-based combination therapy (ACT). Most anemic phenotypes (60.1%) were transfused with whole blood. Antipyretics were used most frequently (52.7%), followed by antispasmodics (44.9%), and 21 patients (12.9%) received a serum glucose infusion.